August 2026
Health Matters, Q3 2026
An experimental weight loss drug generating significant interest, an active foodborne outbreak, a newly approved cardiovascular medication, and several evidence reviews on subjects where the popular discussion has outrun the clinical science.
- Retatrutide: The Most Powerful Weight Loss Drug in Development, And Why You Should Wait
- Cyclospora: A Major Foodborne Outbreak Is Spreading Across the United States
- Enlicitide: The First Oral PCSK9 Inhibitor, Now FDA-Approved
- Ultra-Processed Foods and Your Brain: Research That’s Getting Harder to Ignore
- Longevity Medicine: What’s Real, What’s Expensive, and What’s Both
- Your Smartwatch Says You Have AFib. Now What?
- American Sunscreens Are Finally Getting Better, What You Need to Know
- Ask Your GMP Doctor
- Four More Things Worth Knowing
- Your Quarterly Wellness Calendar